AstraZeneca announced that the FDA has approved Lokelma, formerly ZS-9, for the treatment of hyperkalemia in adults.3 Hyperkalemia is a serious condition characterized by high levels of potassium in the blood. Lokelma is a highly selective, oral potassium-removing agent. The FDA approval comes on the back of Lokelma receiving authorization from the European Commission for the treatment of hyperkalemia in adult patients and it is supported by data from three double-blind, placebo-controlled trials and two open-label long-term trials.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.